Albany, NY — 02/06/2018 — This research report offers a comprehensive analysis of the “Global Market Study on Gastrointestinal Stromal Tumor: Stomach Indications to Account for Largest Revenue Share during 2017-2026″The main objective of this report is to deliver insightful information and clear-cut facts pertaining to the growth trajectories of the market.
Request to view Sample Report @ https://www.mrrse.com/sample/4291
Gastrointestinal stromal tumors (GISTs) are known as one of the most common mesenchymal tumors in the world. According to the World Health Organization, the estimated incidence rate of gastrointestinal stromal tumors is 14.5 per million, and is prevalent in 129 people from a sample of a million, in the United States. Over the past decade, the understanding, awareness and treatment of GISTs has witnessed a tremendous progress. The pathophysiology of gastrointestinal stromal tumors is being studied actively across medical research institutes and organizations across the globe. Gastrointestinal stromal tumors account for less than one percent of all the GI tract tumors in the world. An exclusive study developed by Persistence Market Research projects that by the end of 2026, the global market for gastrointestinal stromal tumor will be worth over US$ 1.5 Bn. During the forecast period, 2017-2026, the global gastrointestinal stromal tumor market will expand at a robust CAGR of 6.6%.
Stomach Indications to Account for Highest Revenues
Being benign, at most times, gastrointestinal stromal tumors may occur in all parts of the gastrointestinal tract. Yet, the stomach is the most common localization for incidence of gastrointestinal stromal tumors. In terms of indication, the report projects that a majority of treatment and diagnosis for gastrointestinal stromal tumor will be directed to remove the tumor from the stomach. In 2017, nearly 60% of revenues procured in the global gastrointestinal stromal tumor market will be accounted by stomach indication.
Hospitals to Represent Largest End-users
With developments in clinical practice guidelines, the treatment of gastrointestinal stromal tumor is largely executed in hospitals. Extended post-treatment hospitalization period and high morbidity of GISTs continue to fuel the presence of hospitals as end-users in the global gastrointestinal stromal tumor market. By the end of 2026, over US$ 480 Mn worth of revenues will be generated from treating GISTs in hospitals across the globe. Over the forecast period, specialized cancer treatment centers will also emerge as a leading end-user in the global gastrointestinal stromal tumor market.
Browse Full Report with TOC @ https://www.mrrse.com/gastrointestinal-stromal-tumor-market
Chemotherapy to Remain Sought-after Treatment for GISTs
Treatment of gastrointestinal stromal tumor is multidisciplinary, entailing the involvement of medical oncologists, surgeons, radiologist, as well as pathologists. Until now, the role of radiotherapy in treatment of gastrointestinal stromal tumor remains decisively unestablished. For being inoperable, patients suffering from this malignant tumor opt for symptomatic treatments such as conventional chemotherapy. The study projects that over the forecast period, chemotherapy treatment of gastrointestinal stromal tumor across the world will register a strong revenue growth, reflecting a CAGR of 6.3%.
Leading pharmaceuticals companies and medical device manufacturers are actively partaking in the global gastrointestinal stromal tumor market, consolidating its expansion through 2026. Although, the current competition backdrop in the global market for GISTs witnesses the presence of only handful of companies, namely Novartis AG, Sun Pharmaceutical Industries Limited, Pfizer Inc., Bayer Aktiengesellschaft, and NATCO Pharma Limited. These companies are mostly based in the US and Europe. The study further anticipates that by 2026, North America will represent the largest market for gastrointestinal stromal tumors. Unhealthy dietary lifestyles, growing use of food additives, and prevalence of genetic disorders will be mainly responsible in driving the growth of North America's gastrointestinal stromal tumor market. During the forecast period, the gastrointestinal stromal tumor market in North America is estimated to grow at a CAGR of 6.9%.
Enquire about this Report @ https://www.mrrse.com/enquiry/4291
Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE's repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207
United States Telephone: +1-518-730-0559
Email: [email protected]
Read More Industry News At: https://www.industrynewsanalysis.com/
Latest posts by Jasmine Petters (see all)
- American Academy of Thermology 2018 Annual Scientific Session Awarded 6.5 hours of AMA PRA Category 1 CME - May 20, 2018
- Strong Programme Raises Profile of the Maritime Standard Ship Finance and Trade Conference - May 20, 2018
- Pegasus Food Futures Announces Appointment of Stefanie Paterson as Head of Human Resources - May 20, 2018